This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
Genomic Biomarker Testing
PEACE-3 Trial
PROfound Trial
PSMAfore Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
CAPItello-281 Trial
PSMAddition Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
BOND-003 Cohort P
CORE-001 Study
CORE-008
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Daniel D. Joyce, MD, MS
Bladder Cancer
Non-Muscle Invasive Bladder Cancer
Ashish Kamat, MD
Muscle-Invasive Bladder Cancer
Advanced & Metastatic Bladder Cancer (mUC)
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Biochemical Recurrence Prostate Cancer
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
Testicular, Penile & Rare GU Malignances
Testicular Cancer
Science in GU Oncology
Bishoy M. Faltas, MD
Functional Urology
Functional Urology
Alan J. Wein, MD, PhD (hon.)
Urologic Catheters - CAUTI Challenges
Videos
Exclusives
Conferences
Disparities: Social Determinants of Health
Exclusive Collaborations
Health Policy in Urological Diseases
Independent Medical Education
Journal Clubs
Practice Guidelines Reviews
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Functional Urology
Men's Health
Pelvic Health
Actionable Clinical Data
Bladder Cancer
NMIBC with CIS: Evidence, Practice & Emerging Research
Risk-Stratified NMIBC Management
Trials in Progress
Prostate Cancer
Localized Prostate Cancer
CLARIFY
ESCAPE
FORT
NRG-GU 0101
RTIRE
High Risk BCR HSPC
ARASTEP
Oligometastatic Prostate Cancer
METANOVA
mHSPC
ARASEC
ASPIRE
MEVPRO-3
mCRPC
ECLIPSE
LEGION-100
MEVPRO-1 & 2
PROMISE
SECuRE
Bladder Cancer
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2026
ASCO 2026
AUA 2026
APCCC 2026
PSMA and Beyond 2026
All Conferences
View All
PCF
UroAlert - GU Oncology Daily
July 02, 2026
Videos
Peer-to-Peer Clinical Conversations
BCG-Unresponsive NMIBC Treatment Options and Practical Decision-Making - Siamak Daneshmand
Siamak Daneshmand
Siamak Daneshmand reviews treatment selection for BCG-unresponsive non-muscle invasive bladder cancer, covering currently available agents.
View
Implementing Radioligand Therapy in a Urology Practice: A Discussion of Practical, Regulatory, and Team Considerations - Neal Shore
Neal Shore
Oliver Sartor interviews Neal Shore about implementing radioligand therapy in community urology practice.
View
Beyond the Abstracts
Real-World Comparison of the Effectiveness and Safety of Immune-Based Combinations in Elderly Patients with Advanced Renal Cell Carcinoma (ARON-1 Study) - Beyond the Abstract
Population-Based Outcomes of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer in Older Adults - Beyond the Abstract
Conference Coverage
ASCO 2026: Advancing Treatment of Low Grade Upper Tract Urothelial Carcinoma with Padeliporfin Vascular Targeted Photodynamic Therapy (VTP): The ENLIGHTED Phase 3 Trial
ASCO 2026: Avelumab + Sacituzumab Govitecan versus Avelumab Monotherapy as First Line Maintenance Treatment for Advanced Urothelial Carcinoma: Updated Subgroup Analyses of JAVELIN Bladder Medley Based on Metastatic Sites
AUA 2026: Practice-Changing, Paradigm-Shifting Clinical Trials in Urology: A Non-Viral Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS, with or Without Papillary Disease: Pivotal Phase 2 Interim Results of Detalimogene Voraplasmid
SES AUA 2026: Application of Machine Learning Models for Predicting Postoperative Ileus after Radical Cystectomy
EAU 2026: International Delphi Consensus on UTUC Management: The IMPACT UTUC Project
Articles
Editor Selected Abstracts and Commentaries
Bladder Cancer
Impact of Social and Structural Determinants of Health on Bladder Cancer Outcomes: Focus on Non-Muscle-Invasive Disease.
Management of High-Risk Non-Muscle-Invasive Bladder Cancer.
Guidelines of the Oncology Committee of the French Association of Urology (CCAFU) and the Infectious Diseases Committee of the French Association of Urology (CIAFU) for Intravesical Instillation of Mitomycin C, Epirubicin, and BCG in NMIBC.
Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.
International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer - Beyond the Abstract
Renal Cancer
Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery.
Bayesian Methods for Subgroup Efficacy and Safety: Application to Japanese Patients in JAVELIN Renal 101.
Prostate Cancer
External validation of the European association of urology biochemical recurrence risk groups to predict mortality after radical prostatectomy or radiation therapy in a North American cohort.
Irreversible electroporation in focal therapy for prostate cancer: current status and future directions.
Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT.
Beyond the tumor: Recurrence-prone radiomics for prognostication in negative PSMA PET/CT scans of prostate cancer.
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.
Upper Tract Tumors
Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study.
Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer Committee - Beyond the Abstract
Testicular Cancer
Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors.
CONNECT WITH US
Questions or Comments? Email us at
editors@urotoday.com
Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523
You are receiving this email because you have chosen to receive emails from UroToday.
Add us to your address book
View this email as a web page
Forward to a colleague
Manage your subscriptions
Unsubscribe
Copyright ©2026 Digital Science Press, LLC
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free